In endometrial carcinoma (21), low-grade breast cancer (22), and gastric adenocarcinoma (15), high expression levels of BUB1 were associated with a good prognosis, whereas in invasive breast cancer (23) and ovarian cancer (24), high expression of BUB1 was associated with an unfavorable prognosis. Here, BUB1 is linked to breast carcinoma.